Maya B Wolf1, Fritz Murray2, Kerstin Kilk3, Jens Hillengass4, Stefan Delorme5, Christiane Heiss6, Kai Neben7, Hartmut Goldschmidt8, Hans-Ulrich Kauczor9, Marc-André Weber10. 1. Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg Germany; Department of Radiology, German Cancer Research Center (Dkfz), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Electronic address: m.mueller-wolf@dkfz.de. 2. Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg Germany. Electronic address: fritz.murray@hotmail.de. 3. Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg Germany. Electronic address: k_fechtner@hotmail.com. 4. Department of Haematology, Oncology, Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. Electronic address: jens.hillengass@med.uni-heidelberg.de. 5. Department of Radiology, German Cancer Research Center (Dkfz), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Electronic address: s.delorme@dkfz-heidelberg.de. 6. Department of Biostatistics, German Cancer Research Center (Dkfz), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Electronic address: c.heiss@dkfz-heidelberg.de. 7. Department of Haematology, Oncology, Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. Electronic address: k.neben@klinikum-mittelbaden.de. 8. Department of Haematology, Oncology, Rheumatology, University Hospital Heidelberg & National Center for Tumour Diseases, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. Electronic address: hartmut.goldschmidt@med.uni-heidelberg.de. 9. Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg Germany. Electronic address: hu.kauczor@med.uni-heidelberg.de. 10. Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg Germany. Electronic address: MarcAndre.Weber@med.uni-heidelberg.de.
Abstract
PURPOSE: To compare sensitivity of whole-body Computed Tomography (wb-CT) and whole-body Magnetic Resonance Imaging (wb-MRI) with Projection Radiography (PR) regarding each method's ability to detect osteolyses in patients with monoclonal plasma cell disease. PATIENTS AND METHODS: The bone status of 171 patients was evaluated. All patients presented with multiple myeloma (MM) of all stages, monoclonal gammopathy of unknown significance (MGUS) or solitary plasmacytoma. Two groups were formed. Group A consisted of 52 patients (26 females, 26 males) with an average age of 62 years (range, 45-89 years) who received, both, PR and wb-CT as part of their diagnostic work-up. Group B comprised 119 patients (58 females, 61 males) averaging 57 years of age (range, 20-80 years) who received, both, PR and wb-MRI. Two experienced radiologists were blinded regarding the disease status and assessed the number and location of osteolyses in consensus. A distinction was made between axial and extra-axial lesions. RESULTS: In group A, wb-CT revealed osteolyses in 12 patients (23%) that were not detected in PR. CT was superior in detecting lesions in patients with osteopenia and osteoporosis. Compared with PR, wb-CT was significantly more sensitive in detecting osteolyses than PR (p<0.001). This was particularly true for axial lesions. Additionally, CT revealed clinically relevant incidental findings in 33 patients (63%). In group B, wb-MRI revealed lesions in 19 patients (16%) that were not detected in PR. All lesions detected by PR were also detected by wb-MRI and wb-CT. Wb-MRI and wb-CT are each superior to PR in detecting axial lesions. CONCLUSION: Wb-CT can detect 23% more focal lesions than PR, especially in the axial skeleton. Therefore, this imaging method should be preferred over PR in the diagnostic work-up and staging of patients with monoclonal plasma cell disease.
PURPOSE: To compare sensitivity of whole-body Computed Tomography (wb-CT) and whole-body Magnetic Resonance Imaging (wb-MRI) with Projection Radiography (PR) regarding each method's ability to detect osteolyses in patients with monoclonal plasma cell disease. PATIENTS AND METHODS: The bone status of 171 patients was evaluated. All patients presented with multiple myeloma (MM) of all stages, monoclonal gammopathy of unknown significance (MGUS) or solitary plasmacytoma. Two groups were formed. Group A consisted of 52 patients (26 females, 26 males) with an average age of 62 years (range, 45-89 years) who received, both, PR and wb-CT as part of their diagnostic work-up. Group B comprised 119 patients (58 females, 61 males) averaging 57 years of age (range, 20-80 years) who received, both, PR and wb-MRI. Two experienced radiologists were blinded regarding the disease status and assessed the number and location of osteolyses in consensus. A distinction was made between axial and extra-axial lesions. RESULTS: In group A, wb-CT revealed osteolyses in 12 patients (23%) that were not detected in PR. CT was superior in detecting lesions in patients with osteopenia and osteoporosis. Compared with PR, wb-CT was significantly more sensitive in detecting osteolyses than PR (p<0.001). This was particularly true for axial lesions. Additionally, CT revealed clinically relevant incidental findings in 33 patients (63%). In group B, wb-MRI revealed lesions in 19 patients (16%) that were not detected in PR. All lesions detected by PR were also detected by wb-MRI and wb-CT. Wb-MRI and wb-CT are each superior to PR in detecting axial lesions. CONCLUSION: Wb-CT can detect 23% more focal lesions than PR, especially in the axial skeleton. Therefore, this imaging method should be preferred over PR in the diagnostic work-up and staging of patients with monoclonal plasma cell disease.
Authors: F Joseph Simeone; Joel P Harvey; Andrew J Yee; Elizabeth K O'Donnell; Noopur S Raje; Martin Torriani; Miriam A Bredella Journal: Skeletal Radiol Date: 2018-09-14 Impact factor: 2.199
Authors: Maja Hinge; Kristian T Andersen; Thomas Lund; Henrik B Jørgensen; Paw C Holdgaard; Tina E Ormstrup; Lone L Østergaard; Torben Plesner Journal: Haematologica Date: 2016-07-06 Impact factor: 9.941
Authors: Marius Horger; Wolfgang M Thaiss; Hendrik Ditt; Katja Weisel; Jan Fritz; Konstantin Nikolaou; Shu Liao; Christopher Kloth Journal: Eur Radiol Date: 2016-11-23 Impact factor: 5.315
Authors: Saravanabavaan Suntharalingam; Christian Mikat; Axel Wetter; Nika Guberina; Ahmed Salem; Philipp Heil; Michael Forsting; Kai Nassenstein Journal: Eur Radiol Date: 2018-01-10 Impact factor: 5.315